Quick Update: Longevity News, Events, and Jobs.
Decibel Therapeutics IPO. Cambrian exits stealth. Methuselah Fund x Clubhouse.
In this (abbreviated) edition of Longevity Marketcap Telemetry
Last Week in Longevity
Long-form research coming soon….
Disclaimer: None of this should be taken as financial advice. This information is for educational purposes only.
***Special Note: I was asked by some of the folks at the NIA to share this grant funding opportunity for organizations looking to conduct clinical trials for therapies in age-related disease:
Deadline is March 3rd, 2021.
Last Week in Longevity
Decibel Therapeutics (NASDAQ:DBTX) IPO. This preclinical-stage hearing loss gene therapy company backed by The Longevity Fund, BlackRock, and others announced their IPO filing on Monday last week and began trading on Friday, raising $127 million at $18 per share. Decibel is developing therapies for genetic, chemotherapy-induced, and age-related hearing loss. Note: Frequency Therapeutics (NASDAQ:FREQ) is in Phase 2 for their age-related hearing loss regenerative therapy — I have a small position in both companies.
Cellvie raises $5M seed round. Cellvie is a Harvard spinout company that develops autologous mitochondrial transfer therapy in order to treat ischemia-reperfusion injury (damage to oxygen-deprived tissue during blood resupply, typically during heart attack, stroke, organ transplant, etc). The seed round was led by Kizoo Technology Capital, Michael Greve’s VC firm.
Cambrian Biopharma comes out of stealth after $60M raise. This portfolio-approach anti-aging biotech company founded by James Peyer (formerly at Apollo Health Ventures) and Christian Angemayer has already brought one of its oncology companies public recently -- Sensei BioTherapeutics (NASDAQ:SNSE). Investors in Cambrian include Mike Novogratz’s Galaxy Digital -- yet another longevity x crypto crossover.
Longeveron (NASDAQ:LGVN) goes public. The Miami-based mesenchymal stem cell company founded by Joshua Hare (University of Miami) raised $26.6M at $10 per share and began trading on February 12th. The stock is presently down 25%.
Reason’s Top Longevity Startup Ideas. Reason, the author of the Fight Aging! blog and founder of Repair Biotechnologies wrote an article on the underserved areas of the longevity biotech industry ripe for new startups to tackle. These areas include gut microbiome, gene therapy platforms, bringing longevity interventions to consumers at a scale, revascularization with stem cells, platforms for removing metabolic waste, and rejuvenating hematopoietic (blood-forming) function.
Biophytis lists on NASDAQ (BPTS). The French clinical-stage developer of plant-compound mimetics to treat sarcopenia and Duchenne muscular dystrophy announced the listing of depository shares on the NASDAQ on February 10th. They also have a COVID trial in the pipeline (who doesn’t?).
Looking for jobs, companies, or investors in the longevity biotechnology industry? Check out my other website LongevityList.com.
Clubhouse Fireside Chat with David Gobel and Sergio Ruiz, Methuselah Fund. Thursday, February 18th, 11AM PST / 2 PM EST. The Methuselah Foundation is one of the oldest1 organizations in longevity (started in 2003) and their venture arm has invested in a number of the most ambitious longevity startups. I will be co-hosting this chat with Jordan Miller (co-founder of Volumetric) and Robert Ziman. All are welcome to join!
Weekly Casual Longevity Biotech Chat on Clubhouse Thursday, February 18th, 1PM PST / 4PM EST. Bolek Kerous (VC at Longevitytech.fund), Robert Ziman, and I are hosting our weekly casual longevity biotech chat on Clubhouse. Previous chats had an amazing number of people from academia and industry drop in including (but not limited to): Alexandra Bause (Apollo), Scott Shandler (Longevity Biotech), Joshua Elkington (Axial), Ethan Perlstein (Perlara), Andrew Brack (UCSF), Matt Scholz (Oisin Biotechnologies), Ryan Bethencourt (Wild Earth, IndieBio), Jordan Miller (Volumetric), among others.
Longevity Leaders 2021 Online Conference May 4th - May 7th, 2021: An industry and academia conference with networking events. Basic passes are free but access to premium online events are paid. Early bird discounts are also available. A great lineup of speakers: Aubrey de Grey, Nir Barzilai, Joao Pedro de Magalhaes, Sergey Young, Ronjon Nag, representatives from Alkahest, Stealth BioTherapeutics, Navitor, and many more.
The Business of Biotech - RA Capital Discussion Session, March 10th, 17th, 24th, 2021. Peter Kolchinsky’s RA Capital has a free course on the business side of biotech and they periodically have a live discussion session on the material. It’s free.
Undoing Aging Postponed to May 26- 28, 2022.One of the best longevity conferences has been postponed another year due to the pandemic. See you all next year in Berlin.
Enjoying this content? Want to learn more about investing in longevity biotechnology? Subscribe to the Longevity Marketcap newsletter. It’s free.
Who’s hiring in the longevity industry? Find more longevity jobs on Longevitylist.com
Sr./Scientist, In Vivo // Repair Biotechnologies // Boston, MA, USA
Associate Director/Director of In Vivo Biology/Pharmacology // BioAge Labs // Richmond, CA, USA
Chief of Staff // BioAge Labs // Richmond, CA, USA , Remote
Research Data Scientist, Computational Biology // BioAge Labs // Richmond, CA, USA
Chief of Staff // AgelessRX // Remote, Ann Arbour, MI, USA
Chief Scientific Officer // Maximon // Zurich, Switzerland
Note: This week’s long-form research content will be emailed separately. I just wanted to get some of the time-sensitive updates (events, grant application notice) out immediately. I anticipate future long form pieces will be much shorter once I get the present (and very large) topic out of the way.